Study to Evaluate the Safety and Effectiveness of Pitolisant on Excessive Daytime Sleepiness in Patients with Myotonic Dystrophy Type 1

Recruiting
18 years - 65 years
All
135 participants needed
1 Location

Brief description of study

The purpose of this research study is to learn about the safety and effectiveness of the study drug called pitolisant when compared with placebo (a tablet that does not contain any study drug) in treating some of the symptoms of Myotonic Dystrophy Type 1, such as excessive daytime sleepiness.

Detailed description of study

The purpose of this research study is to learn about the safety and effectiveness of the study drug called pitolisant when compared with placebo (a tablet that does not contain any study drug) in treating some of the symptoms of Myotonic Dystrophy Type 1, such as excessive daytime sleepiness.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Daytime Sleepiness, Myotonic Dystrophy Type 1
  • Age: 18 years - 65 years
  • Gender: All

Ages 18 to 65 years. Confirmed diagnosis of Myotonic Dystrophy Type 1

Updated on 04 Aug 2024. Study ID: 849131

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center